Patrick Lin, who serves as Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), reported a personal purchase of 1,603 shares of the company’s common stock on March 31, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were bought at $2.535 each, for a total outlay of $4,063.
After the acquisition, Lin directly holds 3,356 shares of Processa stock. He also retains indirect ownership of 1,740 shares through the Lin Family Trust Feb 4, 2024, as disclosed in the filing.
At the time the filing was noted, Processa’s shares were trading at $2.60. That price reflects a 9.8% increase over the prior week, while the stock remains down 49% compared with its level six months earlier.
Beyond the insider transaction, Processa provided an update on its clinical development program. The company said it has completed both enrollment and dosing for a planned interim analysis in its Phase 2 study of NGC-Cap for advanced or metastatic breast cancer. The trial enrolls 20 patients and compares a combination regimen of PCS6422 plus capecitabine against capecitabine alone.
All enrolled patients have had at least one prior cancer treatment, with the median number of previous regimens reported as between two and three. The completion of enrollment and dosing is positioned as a procedural milestone ahead of the interim assessment that will evaluate the combination therapy’s effectiveness.
Financial context included in linked research notes indicates that, on balance-sheet metrics, Processa holds more cash than debt and that the stock appears undervalued at current levels, according to InvestingPro analysis. That analysis also points subscribers to 11 additional ProTips for a more detailed assessment.
Investors will likely watch both insider activity and the forthcoming clinical readouts as they assess the company’s near-term prospects. The insider purchase was modest in dollar terms, while the clinical update confirms the study is moving toward its next analytical phase.